肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

肿瘤突变负荷应用于肺癌免疫治疗的专家共识

2021-11-20 中国临床肿瘤学会非小细胞肺癌专家委员会 中国肺癌杂志

肺癌

肺癌是全球范围内发病率和死亡率最高的恶性肿瘤之一。

中文标题：

肿瘤突变负荷应用于肺癌免疫治疗的专家共识

发布机构：

中国临床肿瘤学会非小细胞肺癌专家委员会

发布日期：

2021-11-20

简要介绍：

肺癌是全球范围内发病率和死亡率最高的恶性肿瘤之一。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs),包括程序性死亡受体1(programmed cell death 1, PD-1)抗体、程序性死亡受体1配体(programmed cell death ligand 1, PD-L1)抗体和细胞毒性T淋巴细胞相关蛋白4(cytotoxic T lymphocyte antigen 4, CTLA-4)抗体,给部分晚期肺癌患者带来了显著的生存获益,改变了晚期肺癌的治疗格局。既往研究表明,PD-1/PD-L1抗体在晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)中的客观缓解率只有20%左右。所以临床亟需可靠的生物标志物协助筛选ICIs潜在获益人群,提高治疗响应率。肿瘤突变负荷(tumor mutational burden, TMB)是除PD-L1表达以外新兴的免疫治疗标志物。肺癌中PD-L1表达与TMB的相关性不大,评估TMB可扩大免疫治疗的获益人群。然而在临床实践中,TMB的检测、阈值的确定和临床指导策略仍然没有形成规范。本共识将对TMB检测和应用场景给出指导性建议,以促进TMB在肺癌免疫治疗中应用的规范化。

相关资料下载：
[AttachmentFileName(sort=1, fileName=肿瘤突变负荷应用于肺癌免疫治疗的专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e3e7c1c0022e62ba, title=肿瘤突变负荷应用于肺癌免疫治疗的专家共识, enTitle=, guiderFrom=中国肺癌杂志, authorId=0, author=, summary=肺癌是全球范围内发病率和死亡率最高的恶性肿瘤之一。, cover=https://img.medsci.cn/20211129/1638166553814_5579292.jpg, journalId=0, articlesId=null, associationId=2163, associationName=中国临床肿瘤学会非小细胞肺癌专家委员会, associationIntro=中国临床肿瘤学会非小细胞肺癌专家委员会, copyright=0, guiderPublishedTime=Sat Nov 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>肺癌是全球范围内发病率和死亡率最高的恶性肿瘤之一。免疫检查点抑制剂(immune checkpoint inhibitors, ICIs),包括程序性死亡受体1(programmed cell death 1, PD-1)抗体、程序性死亡受体1配体(programmed cell death ligand 1, PD-L1)抗体和细胞毒性T淋巴细胞相关蛋白4(cytotoxic T lymphocyte antigen 4, CTLA-4)抗体,给部分晚期肺癌患者带来了显著的生存获益,改变了晚期肺癌的治疗格局。既往研究表明,PD-1/PD-L1抗体在晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)中的客观缓解率只有20%左右。所以临床亟需可靠的生物标志物协助筛选ICIs潜在获益人群,提高治疗响应率。肿瘤突变负荷(tumor mutational burden, TMB)是除PD-L1表达以外新兴的免疫治疗标志物。肺癌中PD-L1表达与TMB的相关性不大,评估TMB可扩大免疫治疗的获益人群。然而在临床实践中,TMB的检测、阈值的确定和临床指导策略仍然没有形成规范。本共识将对TMB检测和应用场景给出指导性建议,以促进TMB在肺癌免疫治疗中应用的规范化。</p>, tagList=[TagDto(tagId=428, tagName=肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=428, guiderKeyword=肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3767, appHits=152, showAppHits=0, pcHits=925, showPcHits=3615, likes=0, shares=24, comments=7, approvalStatus=1, publishedTime=Mon Nov 29 14:20:26 CST 2021, publishedTimeString=2021-11-20, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 29 14:19:57 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 00:44:10 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肿瘤突变负荷应用于肺癌免疫治疗的专家共识.pdf)])
肿瘤突变负荷应用于肺癌免疫治疗的专家共识.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080108, encodeId=649210801085a, content=学习了，对临床有很好的指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bc45572746, createdName=ms4000000559127129, createdTime=Tue Dec 14 22:39:25 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079988, encodeId=025710e9988e4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c651857601, createdName=ms6210040651457422, createdTime=Tue Dec 14 16:32:48 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078935, encodeId=fe1610e89355a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed506396921, createdName=ms8000000249558528, createdTime=Sat Dec 11 01:30:21 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076894, encodeId=dbc610e68949a, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Sat Dec 04 18:00:44 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075287, encodeId=a2ef10e528761, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:02:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-14 ms4000000559127129

    学习了，对临床有很好的指导意义

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080108, encodeId=649210801085a, content=学习了，对临床有很好的指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bc45572746, createdName=ms4000000559127129, createdTime=Tue Dec 14 22:39:25 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079988, encodeId=025710e9988e4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c651857601, createdName=ms6210040651457422, createdTime=Tue Dec 14 16:32:48 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078935, encodeId=fe1610e89355a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed506396921, createdName=ms8000000249558528, createdTime=Sat Dec 11 01:30:21 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076894, encodeId=dbc610e68949a, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Sat Dec 04 18:00:44 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075287, encodeId=a2ef10e528761, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:02:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-14 ms6210040651457422

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080108, encodeId=649210801085a, content=学习了，对临床有很好的指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bc45572746, createdName=ms4000000559127129, createdTime=Tue Dec 14 22:39:25 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079988, encodeId=025710e9988e4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c651857601, createdName=ms6210040651457422, createdTime=Tue Dec 14 16:32:48 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078935, encodeId=fe1610e89355a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed506396921, createdName=ms8000000249558528, createdTime=Sat Dec 11 01:30:21 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076894, encodeId=dbc610e68949a, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Sat Dec 04 18:00:44 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075287, encodeId=a2ef10e528761, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:02:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-11 ms8000000249558528

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080108, encodeId=649210801085a, content=学习了，对临床有很好的指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bc45572746, createdName=ms4000000559127129, createdTime=Tue Dec 14 22:39:25 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079988, encodeId=025710e9988e4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c651857601, createdName=ms6210040651457422, createdTime=Tue Dec 14 16:32:48 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078935, encodeId=fe1610e89355a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed506396921, createdName=ms8000000249558528, createdTime=Sat Dec 11 01:30:21 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076894, encodeId=dbc610e68949a, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Sat Dec 04 18:00:44 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075287, encodeId=a2ef10e528761, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:02:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-04 ms8000000973640961

    1

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080108, encodeId=649210801085a, content=学习了，对临床有很好的指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bc45572746, createdName=ms4000000559127129, createdTime=Tue Dec 14 22:39:25 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079988, encodeId=025710e9988e4, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c651857601, createdName=ms6210040651457422, createdTime=Tue Dec 14 16:32:48 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078935, encodeId=fe1610e89355a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed506396921, createdName=ms8000000249558528, createdTime=Sat Dec 11 01:30:21 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076894, encodeId=dbc610e68949a, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Sat Dec 04 18:00:44 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075287, encodeId=a2ef10e528761, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:02:22 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 微探

    学习学习

    0

相关指南

2021 CHEST指南和专家组报告：肺癌筛查

美国胸科医师学会(ACCP,American College of Chest Physicians) · 2021-11-06

2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗

中国肿瘤科相关专家小组（统称） · 2021-09-10

2021 NICE: 纳武单抗联合伊匹单抗和化疗治疗未经治疗的转移性非小细胞肺癌

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-09-08

非小细胞肺癌分子残留病灶专家共识

中国抗癌协会肺癌专业委员会 · 2021-06-30

2021 AATS专家共识文件：Ⅰ期非小细胞肺癌考虑行肺叶切除术高危患者的定义和评估

美国胸外科协会(AATS,American Association for Thoracic Surgery) · 2021-07-29

肺癌相关性咳嗽诊疗中国专家共识

中国抗癌协会癌症康复与姑息治疗专业委员会(CRPC) · 2021-09-21

拓展阅读

2014 IASLC肺癌分期项目：肺癌TNM分期新数据（第八版）

国际肺癌研究协会(IASLC,International Association for the Study of Lung Cancer) · 2014-09-14

中国原发性肺癌诊疗规范（2015年版）

中华人民共和国国家卫生和计划生育委员会(NHFPC,National Health and Family Planning Commission of China) · 2015-01-29

中国晚期原发性肺癌诊治专家共识(2016年版)

暂未更新 · 2016-04-21

2014 IASLC/ASCO：肺癌患者表皮生长因子受体和间变性淋巴瘤激酶酪氨酸激酶抑制剂的选择性分子检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2016-05-31

2016 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识

中华医学会病理学分会 · 2016-04-30

回生口服液用于非小细胞肺癌围手术期抗凝治疗专家共识（2016版）

中国肿瘤科相关专家小组（统称） · 2016-11-01